Form 4: Inovio Pharmaceuticals Director David B. Weiner Reports Stock Transactions

Director David B. Weiner reports the vesting and settlement of restricted stock units into Inovio Pharmaceuticals common stock.

Summary

• David B. Weiner, a director of Inovio Pharmaceuticals, reported transactions involving restricted stock units.
• On February 26, 2025, 972 restricted stock units vested and were settled into common stock.
• These transactions resulted in Weiner owning 83,481 shares and 84,453 shares of common stock after each transaction.
• The restricted stock units represent a contingent right to receive one share of common stock.
• The vesting schedule for the restricted stock units was spread over three years.
• A 1-for-12 reverse stock split was effected by the Issuer on January 24, 2024.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions, with neutral sentiment.

Industry Context

This filing is a routine disclosure of insider transactions and provides limited insight into the broader industry trends.

Stakeholder Impact

• The vesting of restricted stock units may have a minor dilutive effect on existing shareholders.

Key Dates